A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BLU-5937 FOR THE TREATMENT OF CHRONIC PRURITUS IN ADULT SUBJECTS WITH ATOPIC DERMATITIS (BLUEPRINT)

Registry ID

CL-PR-5937-01

Source registry

HEALTH_CANADA

Status

Closed

Study type

INTERVENTIONAL

Sponsor

BELLUS HEALTH INC

Start date

2021-03-01

Completion date

2022-01-26

Last update

2020-02-18

Conditions

• PRURITIS
• ATOPIC DERMATITIS

Related clinical trials

• A PHASE 2B, MULTICENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CAMOTESKIMAB IN ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
• AN EXPLORATORY PROOF OF CONCEPT STUDY TO ASSESS THE PHARMACOKINETICS/PHARMACODYNAMICS OF NEMOLIZUMAB (CD14152) IN ADULT PARTICIPANTS WITH CHRONIC PRURITUS OF UNKNOWN ORIGIN (CPUO)
• A PHASE 2B, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF JNJ-95597528 FOR THE TREATMENT OF ADULT PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
• A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF GALVOKIMIG IN ADULT STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
• A MULTICENTER, RANDOMIZED, PARTICIPANT- AND INVESTIGATOR -BLINDED, PLACEBO-CONTROLLED, PHASE 2A STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF GIA632 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
• A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, DOSE-RANGING STUDY WITH AN OPEN-LABEL PERIOD INVESTIGATING THE EFFICACY AND SAFETY PROFILE OF KT-621 ADMINISTERED ORALLY TO PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS.

View on source registry